Valuation: Virbac

Capitalization 3.02B 3.51B 2.76B 2.61B 4.82B 339B 4.9B 32.74B 12.8B 160B 13.16B 12.87B 557B P/E ratio 2026 *
17.9x
P/E ratio 2027 * 15.9x
Enterprise value 3.14B 3.65B 2.87B 2.71B 5.01B 352B 5.1B 34.05B 13.31B 167B 13.68B 13.39B 579B EV / Sales 2026 *
2.01x
EV / Sales 2027 * 1.83x
Free-Float
49.03%
Yield 2026 *
0.47%
Yield 2027 * 0.59%
1 day+1.27%
1 week+4.20%
Current month-3.10%
1 month-6.13%
3 months-1.91%
6 months+1.41%
Current year+0.70%
1 week 340
Extreme 340
364
1 month 339
Extreme 339
384.5
Current year 326.5
Extreme 326.5
389.5
1 year 296
Extreme 296
389.5
3 years 232.5
Extreme 232.5
400
5 years 215
Extreme 215
448.5
10 years 102.1
Extreme 102.1
448.5
Manager TitleAgeSince
Chief Executive Officer 46 2025-08-31
Chief Executive Officer 50 2024-09-26
Chief Operating Officer 64 2021-12-31
Director TitleAgeSince
Chairman 61 2006-03-31
Director/Board Member 68 2010-07-27
Director/Board Member 65 2017-09-04
Change 5d. change 1-year change 3-years change Capi.($)
+1.27%+4.20%+17.26%+17.26% 3.45B
+1.00%+3.60%-51.38%-55.61% 33.09B
+5.30%-2.71%+57.72%+145.01% 9.89B
-1.55%-10.39%+15.62%+41.26% 5.27B
-2.12%-9.29%+93.58%+29.78% 2.27B
+0.84%+0.50%-26.18%-7.18% 1.67B
-0.27%-7.57%+40.12%+139.79% 1.38B
-1.05%-4.28%-31.27%-13.84% 1.14B
-1.12%-3.41%+0.28%-45.63% 1.07B
-0.28%-2.10%-16.36%-40.16% 988M
Average +0.20%-2.48%+9.94%+21.07% 6.02B
Weighted average by Cap. +1.25%-0.76%-13.53%+0.24%

Financials

2026 *2027 *
Net sales 1.56B 1.81B 1.43B 1.35B 2.49B 175B 2.53B 16.91B 6.61B 82.74B 6.8B 6.65B 288B 1.64B 1.91B 1.5B 1.42B 2.62B 184B 2.67B 17.8B 6.96B 87.08B 7.15B 7B 303B
Net income 167M 194M 153M 145M 267M 18.77B 272M 1.81B 709M 8.88B 729M 714M 30.87B 192M 224M 176M 167M 307M 21.61B 313M 2.09B 817M 10.22B 839M 822M 35.54B
Net Debt 121M 141M 111M 105M 193M 13.58B 197M 1.31B 513M 6.43B 528M 516M 22.35B -23.01M -26.75M -21.05M -19.91M -36.75M -2.58B -37.39M -250M -97.61M -1.22B -100M -98.21M -4.25B
Logo Virbac
Virbac specializes in the research, production and marketing of veterinary medicines. Net sales break down by family of products as follows: - pet medications (60.7%): pest control drugs, vaccines, antibiotics, anesthetics, anti-inflammatory drugs, mouth/dental care products, ophthalmologic and dermatological products intended for dogs, cats, horses, birds, rodents, etc. The group also offers foods and electronic identification chips; - livestock medications (39.3%): pest control drugs and antibiotics intended for cattle, sheep, pigs, poultry, etc. Net sales are distributed geographically as follows: Europe (41.6%), Latin America (15.2%), North America (13.6%), India/Africa/Middle East (12.2%), Eastern Asia (10.5%) and Pacific (6.9%).
Employees
6,442
Date Price Change Volume
26-05-20 360.00 +1.27% 3,486
26-05-19 355.50 +2.89% 6,149
26-05-18 345.50 -1.29% 9,826
26-05-15 350.00 +2.34% 6,773
26-05-14 342.00 +0.29% 1,477
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
360.00EUR
Average target price
413.00EUR
Spread / Average Target
+14.72%

Quarterly revenue - Rate of surprise